- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
Snapshot for Dendreon Corp (DNDN)
| Open: | 4.1300 | Day's Range: | 4.0200 - 4.1300 | Volume: | 1,934,004 |
|---|---|---|---|---|---|
| Previous Close: | 4.1000 | 52wk Range: | 3.6900 - 7.9400 | 1-Yr Rtn: | -43.33% |
Key Statistics for DNDN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -2.1100 |
| Est. EPS (USD) (12/2013) | -1.4290 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 643.01 |
| Shares Outstanding (M) | 157.60 |
| 30 Day Average Volume | 4,581,523 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | 1.9631 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/30/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for DNDN
Company Profile & Key Executives for DNDN
Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. The Company combines knowledge in immunology and antigen engineering with proprietary cell separation technologies to develop therapeutic vaccines that induce cell-mediated immunity, the body's key defense against cancer.
| John H JohnsonChairman/President/CEO | Gregory T SchiffmanExec VP/CFO/Treasurer |
| Lindsay RoccoExec VP:Corporate Communications | Joseph I Depinto "Joe"Exec VP:Global Commercial Ops |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
DNDN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page